Friday, February 01, 2019 2:53:08 PM
From the Roche earnings call transcript:
"Bill Anderson
And so we're talking about the fixed dose of Herceptin plus PERJETA. And I think this is -- I mean, it's an attractive option, particularly for patients who aren't receiving chemo, which, for example, in the adjuvant setting, they're not getting chemo, and so it's a choice between coming in and getting an infusion of Herceptin and an infusion of PERJETA or coming in with a really simple injection with Halozyme. And we think, over time, it's going to make sense because it's just -- it's better. It's more convenient.
And I think it may be the kind of thing that takes a while to convert if physicians are comfortable with the practice of doing the multiple infusions. But there's a lot of patients getting a lot of infusions there. I mean, Herceptin plus PERJETA is the standard of care in metastatic breast cancer, standard of care in early breast cancer. And it starts to get pretty compelling, even more so than the switch from, say, Herceptin IV to Herceptin SubQ because there, you're just replacing one infusion and now you've got an opportunity to replace two.
...
Mark Purcell
It's Mark Purcell from Morgan Stanley. I was just going to follow up on the same subject there. I guess the life cycle management behind the CD20 franchise is very clear, that hurts your franchise slightly less, that a bispecific earlier in development better. Just in terms of the timing, it doesn't look like you're going to launch a subcut Herceptin in the U.S. You're going to go straight to the combination. And given you have visibility on three of the five players, and the first one, the biosimilar's going to be launched with very limited capacity for the first few years, I just wondered, obviously, you guide on risk rather than likely outcome, but if the decision to go with a 2020 launch on the combination is related to what could be a greater window than currently people are modeling.
...
Bill Anderson
Okay. That's quite a list. Actually, the first answer is there's a relatively straightforward answer. We are launching Herceptin SubQ in the U.S. It -- yes, it was a long journey because it wasn't clear the regulator was going to support it, and then we had to get it -- and then we had a priority on resources in EU because it was an ongoing launch. So basically, we were -- yes, we were delayed on time lines, but we are planning to bring it to market. I don't have an update on the timing, but -- and so there have been no decisions about prioritizing the fixed dose combination over SubQ Herceptin. We're going to bring SubQ Herceptin as fast as we can clear the regulatory process, and then we'll bring the fixed dose also as fast as we can bring it."
Recent HALO News
- Halozyme to Report First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 04/23/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 09:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:01:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 09:08:09 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:49:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 09:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:03:54 PM
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 02/20/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:47:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:41:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:39:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:12:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:19:50 AM
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results • PR Newswire (US) • 02/08/2024 09:30:00 PM
- Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • PR Newswire (US) • 01/29/2024 09:15:00 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM